Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Feb 22, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how a medication called GLP-1 agonist affects body fat in people who are having weight loss surgery, known as bariatric surgery. The goal is to see if those taking the GLP-1 medication have different levels of a hormone called oxytocin compared to those who are not taking it. Understanding these effects can help in managing obesity and preventing health issues related to weight gain.

To participate in the trial, you need to be at least 18 years old, have a body mass index (BMI) over 35 with at least one related health condition, or a BMI over 40. You should also be able to read and understand the study information. If you are in the group receiving GLP-1, you must have been taking it for at least three months; if you are in the other group, you shouldn’t have taken GLP-1 before. Participants will undergo assessments to track the effects of the medication on their body fat and hormone levels. It’s important to note that pregnant or breastfeeding women, as well as those under guardianship or in custody, cannot join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient over 18 years of age.
• • Patient able to read and understand the information/consent leaflet.
• • Patient with BMI \> 35 with at least one comorbidity. Or BMI \> 40
• • Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
• • Membership of a social security scheme
• • Patient's signed informed consent
• • For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
• • For non-GLP-1 analogue group: never taken GLP-1 analogues.
• Exclusion Criteria:
• • Pregnant or breast-feeding women.
• • Vulnerable patients (under guardianship)
• • Patients deprived of liberty